In contrast, some clinical evidence indicates that the constitutive upregulation of Nrf2 is related not only to cancer progression but also to resistance to traditional therapy and worse outcomes in NSCLC [164, 168]. This evidence concerns the gene NFE2L2 and non-small cell lung carcinoma.